Lauren Silvis has joined personalized medicine company Tempus Labs Inc. (Chicago, Ill.) as SVP of external affairs. Silvis was FDA chief of staff from May 2017 to June 2019; she also served for two years...

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...

Two weeks after raising €40 million ($45.7 million) in a series B round in preparation for its first clinical trials which are slated for next year, Inflazome Ltd. (Dublin, Ireland) hired Thomas Jung as its...

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain...

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash. In addition to Oncaspar, Servier will gain...

Symphogen A/S (Copenhagen, Denmark) reported data from a Phase II trial in 254 patients with advanced metastatic colorectal cancer (mCRC) and acquired resistance to marketed anti-EGFR mAbs showing that low- and high-dose IV Sym004 each...